GoDx: Advancing the Future of Rapid Point-of-Care Diagnostics

Healthcare is moving toward a future where accurate diagnostic answers are available faster, closer to the patient, and with fewer barriers. Traditional laboratory testing remains essential, but delays in transportation, processing, and reporting can slow critical healthcare decisions. This is where point-of-care diagnostics are changing the landscape.

GoDx Inc., an emerging biomedical diagnostics company headquartered in Madison, Wisconsin, is helping lead this transformation. Founded by Dr. Chang-Hee Kim, the company specializes in developing low-cost, rapid, point-of-care molecular testing technologies designed to detect infectious pathogens and antimicrobial resistance (AMR) without requiring complex laboratory infrastructure.

At GoDx, the mission is centered on making advanced diagnostic technology more accessible, practical, and efficient for healthcare providers and patients alike. By focusing on innovative molecular diagnostic solutions, the company is helping bridge the gap between laboratory-grade accuracy and real-world clinical convenience.

Why Speed Matters in Diagnostics

In infectious disease management, timing can significantly impact patient outcomes. Faster identification of pathogens allows healthcare professionals to begin targeted treatment sooner, reduce unnecessary antibiotic use, and improve infection control efforts.

Point-of-care diagnostic tools are designed to simplify this process by bringing testing capabilities closer to where care happens — whether in clinics, community healthcare settings, rural areas, or emergency response environments.

GoDx recognizes that healthcare providers need solutions that are not only accurate, but also practical, scalable, and easy to implement.

GoAMP™ Technology: Simplifying Molecular Diagnostics

Modern molecular diagnostics have transformed how healthcare professionals detect infectious diseases. Technologies such as DNA and RNA-based testing can provide highly sensitive detection of pathogens and antimicrobial resistance markers.

At the center of GoDx innovation is the proprietary GoAMP™ Nucleic Acid Amplification Technology (NAAT) platform. This technology amplifies viral or bacterial RNA and DNA exponentially while eliminating the need for traditional PCR laboratory equipment such as heat blocks or thermocyclers.

The GoAMP™ platform utilizes a simple load-and-go workflow with lateral flow paper test strips that resemble at-home pregnancy tests. The system provides positive or negative results directly on the strip, often within 30 minutes.

According to preclinical studies, the platform demonstrates sensitivity levels up to 125 times higher than standard PCRD methods while simplifying testing procedures for real-world healthcare environments.

GoDx continues to develop innovative approaches that support rapid detection while reducing the complexity often associated with traditional laboratory systems. One of the key advantages of the technology is the ability to extract and identify pathogen target sequences directly from raw samples without requiring culture-based laboratory processing.

The company’s work in lateral flow assays, point-of-care diagnostics, and infectious disease detection reflects a growing need for portable and efficient healthcare solutions.This approach is especially important in settings where access to centralized laboratory infrastructure may be limited.

Expanding Applications Across Healthcare and Public Health

Accessible diagnostics are essential for improving healthcare equity worldwide. In many regions, delayed or unavailable testing contributes to poor outcomes and the spread of infectious diseases.

GoDx is expanding its diagnostic platform across multiple healthcare and public health applications:

● Go-GutDX®: A rapid stool-based diagnostic strip engineered to identify gastrointestinal pathogens and antimicrobial resistance genes simultaneously.

● STI Testing: Portable molecular diagnostics designed for rapid detection of chlamydia, gonorrhea, and trichomoniasis.

● GoDNA™ Kit: A broader diagnostic platform supporting respiratory disease screening, including COVID-19 applications, and environmental water pathogen surveillance.

The company is also collaborating with the Defense Health Agency (DHA) to develop field-portable water surveillance diagnostics for military and public health deployment.

GoDx supports the broader goal of expanding diagnostic access through technologies designed for simplicity, affordability, and usability. By focusing on portable diagnostic systems and rapid testing methods, the company contributes to healthcare solutions that can support both local clinics and larger public health initiatives.

As antimicrobial resistance continues to grow as a global concern, rapid pathogen identification and resistance detection are becoming increasingly important in clinical decision-making.

Industry Recognition and Strategic Growth

Healthcare innovation is not only about advanced science — it is also about usability. Diagnostic tools must work efficiently in real-world healthcare environments.

GoDx has received national recognition for its diagnostic innovation and patient impact. The company was awarded the American Gastroenterological Association (AGA) Tech Summit Shark Tank Contest for its potential to improve gastrointestinal diagnostics and patient care.

In addition, GoDx has received multiple federal research grants through the National Institutes of Health (NIH) and the Small Business Innovation Research (SBIR) program. In 2025, the company joined the BARDA-sponsored Rapid Response Partnership Vehicle (RRPV), helping accelerate the deployment of next-generation biodefense and pandemic readiness technologies.

As a Wisconsin-certified Qualified New Business Venture (QNBV), GoDx continues to expand opportunities for investment, clinical development, and strategic partnerships.

GoDx focuses on solutions that prioritize:

● Rapid turnaround times

● Simplified workflows

● Reliable molecular detection

● Portable testing capabilities

● Accessibility for diverse healthcare settings

This practical approach allows healthcare professionals to make informed decisions with greater confidence and efficiency.

Looking Ahead: Faster Diagnostics, Better Outcomes

The future of diagnostics will continue to move toward faster, more decentralized testing solutions. As healthcare systems adapt to growing demands for accessibility, efficiency, and precision, point-of-care technologies will play an increasingly important role. GoDx remains committed to advancing diagnostic innovation through technologies that support clinicians, improve patient care, and expand access to timely healthcare information.

By combining scientific research with practical application, the company continues to contribute to a healthcare future where critical diagnostic insights are available when and where they are needed most.

As healthcare systems continue shifting toward decentralized and rapid diagnostic solutions, GoDx remains focused on advancing technologies that improve accessibility, efficiency, and clinical decision-making.

By combining scientific innovation with practical usability, the company is contributing to a future where high-quality diagnostic information is available quickly, accurately, and wherever it is needed most.

Contact 

For research partnerships, clinical study inquiries, or product evaluation, visithttps://www.godiagnostic.com/ or contact GoDx directly at info@GoDiagnostic.com.

Address: 510 Charmany Dr, Suite 265, Madison, WI 53719